Clinical studies indicate that patients in early stages of GC frequently exhibit increased serum levels of these biomarkers, particularly PG I, with reported concentrations close to 70.95 μg L−1 and a PG I/PG II ratio of approximately 2.99 μg L−1. The gene discussed is JUP; the disease is gastric cancer.